Literature DB >> 32334097

Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: A review.

Sara Cunha1, Cláudia Pina Costa1, João Nuno Moreira2, José Manuel Sousa Lobo1, Ana Catarina Silva3.   

Abstract

Quality-by-design (QbD) approach has been applied to optimize lipid-based nanosystems formulations, including solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and nanoemulsions, besides being increasingly requested by regulatory authorities. Different mathematical models and statistical tests have been used, with similar conclusions regarding the parameters that influence the physical features of the resulting nanosystems. These include, variations in composition (e.g. lipid(s) and/or emulsifier(s)) and manufacturing parameters (e.g. emulsification rate and/or time, sonication amplitude and/or time, and homogenization pressure and/or cycles). These are critical parameters that influence nanoparticle/globule mean size, polydispersity index, zeta potential, drug encapsulation efficiency and in vitro drug release. This review addresses the concepts and applications of QbD for the development of lipid-based nanosystems, reporting successful examples published in the last 2 years. Although, some limitations have been identified, it is expected that in the upcoming years the application of QbD in pharmaceutical development will be an established approach.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nanoemulsions; Nanostructured lipid carriers; Optimization of formulations; Quality by design; Solid lipid nanoparticles

Mesh:

Substances:

Year:  2020        PMID: 32334097     DOI: 10.1016/j.nano.2020.102206

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  7 in total

Review 1.  Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels.

Authors:  Sara Cunha; Ben Forbes; José Manuel Sousa Lobo; Ana Catarina Silva
Journal:  Int J Nanomedicine       Date:  2021-06-29

Review 2.  Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation.

Authors:  Felipe M González-Fernández; Annalisa Bianchera; Paolo Gasco; Sara Nicoli; Silvia Pescina
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

Review 3.  The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development.

Authors:  Thelvia I Ramos; Carlos A Villacis-Aguirre; Katherine V López-Aguilar; Leandro Santiago Padilla; Claudia Altamirano; Jorge R Toledo; Nelson Santiago Vispo
Journal:  Pharmaceutics       Date:  2022-01-21       Impact factor: 6.321

4.  Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating In Vitro Specification, and In Vivo Scrutinization.

Authors:  Ali Sartaj; Largee Biswas; Anita Kamra Verma; P K Sahoo; Sanjula Baboota; Javed Ali
Journal:  Biomed Res Int       Date:  2022-02-03       Impact factor: 3.411

5.  Novel Phenobarbital-Loaded Nanostructured Lipid Carriers for Epilepsy Treatment: From QbD to In Vivo Evaluation.

Authors:  Sebastian Scioli-Montoto; Maria Laura Sbaraglini; Jose Sebastian Cisneros; Cecilia Yamil Chain; Valeria Ferretti; Ignacio Esteban León; Vera Alejandra Alvarez; Guillermo Raul Castro; German Abel Islan; Alan Talevi; Maria Esperanza Ruiz
Journal:  Front Chem       Date:  2022-08-17       Impact factor: 5.545

Review 6.  The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.

Authors:  Reem Abou Assi; Ibrahim M Abdulbaqi; Chan Siok Yee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-04

7.  Optimization of the Micellar-Based In Situ Gelling Systems Posaconazole with Quality by Design (QbD) Approach and Characterization by In Vitro Studies.

Authors:  Meltem Ezgi Durgun; Burcu Mesut; Mayram Hacıoğlu; Sevgi Güngör; Yıldız Özsoy
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.